# Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease

> **NCT02931305** · PHASE1 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 30 (estimated)

## Conditions studied

- Osteoporosis
- Cardiovascular Disease

## Interventions

- **DRUG:** Epimedium Prenylflavonoids Extract
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02931305
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2017-01
- **Final completion:** 2017-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02931305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02931305, "Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02931305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*